BTIG analyst Mark Massaro lowered the firm’s price target on Ginkgo Bioworks (DNA) to $5 from $9 and keeps a Sell rating on the shares. The company announced the divestiture of its biosecurity business, which limits its guidance to cash burn, the analyst tells investors in a research note. BTIG adds, however, that it is now looking for greater visibility into Ginkgo’s progress to build out and monetize autonomous labs.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DNA:
- Ginkgo Bioworks Bets on Autonomous Labs Amid Headwinds
- Limited Visibility and Questionable Revenue Quality Underscore Sell Rating on Ginkgo Bioworks
- Ginkgo Bioworks Divests Biosecurity Unit, Retains Minority Stake
- Ginkgo Bioworks Holdings, Inc. Reports Earnings: Did it Beat Estimate Forecasts?
- Ginkgo Bioworks expects total cash burn of (150M)-(125M) in 2026